The standardization of treatment and diagnosis, especially the extensive use of immunohistochemical markers such as CyclinD1 and Sox11, make it helpful to discriminate MCL from other B‐cell lymphomas. This evidence concerns the gene SOX11 and B-cell non-Hodgkin lymphoma.